Altimmune completes dosing in the Phase 2 MOMENTUM trial
Altimmune has completed dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of...
top of page
Browse by category
Search
Altimmune begins MOMENTUM obesity trial for Pemvidutide
Altimmune has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide in...
Browse by tag
bottom of page